Handelsavisen
prelaunch
Companies ›Healthcare ›ACL.AX
AC
ACL.AX — ASX Healthcare Facilities & Services

Acl.Ax

A$2,21
Open in Charts → Attach watcher ⌖
— —
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
9,49 %
Op margin
8,9 %
ROE
18,9 %
Net margin
4,4 %
Debt / equity
1,69
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

ACL.AX operates in the healthcare sector, providing services and equipment within the healthcare facilities and services industry.

Business. ACL.AX operates in the healthcare sector, providing services and equipment within the healthcare facilities and services industry.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
HOLD7 analysts
1 buy6 hold0 sell
Avg 12m price target2,57

Analyst recommendations

7 analysts · consensus Hold
Buy1
Hold6
Sell0
12-month price target
2,57
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
7 analysts · indicative
Ownership
—
not yet wired
Profitability→
18,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ACL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ACL.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ACL.AX operates in the healthcare sector, providing services and equipment within the healthcare facilities and services industry.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    ACL.AX maintains a capital structure with a debt-to-equity ratio of 1.69, indicating a significant reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.55, suggesting potential challenges in meeting short-term obligations. The return on equity of 0.1893 and return on assets of 0.0564 indicate that the company is generating returns, but at a moderate level compared to industry benchmarks.

    The company's profitability is reflected in its operating income of 66,136,000 AUD and net income of 32,430,000 AUD, which are key indicators of its financial health. However, these figures should be compared against the industry's preferred metrics to assess performance relative to peers. The gross profit of 613,020,000 AUD suggests that the company is effectively managing its production costs.

    ACL.AX's revenue is primarily concentrated in the healthcare services and equipment segment, with no specific geographic breakdown provided in the available data. The company's growth trajectory is expected to be influenced by its current financial performance and market conditions. Analysts have provided a mean price target of 2.57 AUD and a median price target of 2.40 AUD, indicating a range of expectations for the company's future performance.

    The risk assessment for ACL.AX highlights a medium liquidity risk and a low dilution risk. The company's free cash flow of 135,505,000 AUD and operating cash flow of 182,801,000 AUD are positive indicators of its ability to generate cash. However, the negative net cash position after subtracting total debt is a key flag that may affect its financial stability.

    Recent events and filings have not been detailed in the provided data, but the company's financial snapshot and risk assessment provide a comprehensive view of its current status.

    Key takeaways
    • ACL.AX has a debt-to-equity ratio of 1.69, indicating a significant reliance on debt financing.
    • The company's return on equity is 0.1893, suggesting moderate profitability.
    • ACL.AX's liquidity position is characterized by a current ratio of 0.55, which may pose challenges in meeting short-term obligations.
    • Analysts have provided a mean price target of 2.57 AUD, indicating a range of expectations for the company's future performance.
    • margin_outlook_rationale: The company's gross profit margin is expected to remain stable due to effective cost management.
    • rd_outlook_rationale: Research and development expenditures are not detailed, but the company's focus on healthcare services suggests ongoing innovation.
    • capex_outlook_rationale: Capital expenditures are expected to be minimal, as indicated by the negative value in the financial snapshot.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$2,21
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    A$171.4M
    Net cashⓘ
    -A$268.9M
    Current ratioⓘ
    0.6
    Debt / equityⓘ
    1.7
    ROAⓘ
    5.6%
    ROEⓘ
    18.9%
    Cash conversionⓘ
    564.0%
    CapEx / revenueⓘ
    -1.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,16
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    7
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,16
    Revenue—no estimate—no estimate737,1M AUD
    Operating income—no estimate—no estimate64,9M AUD
    Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution7 analysts
    Strong buy0
    Buy1
    Hold6
    Sell0
    Strong sell0
    12-month price targetA$2,57 · Median A$2,40
    Low A$2,25High A$3,85
    Operating income · consensus64,9M AUD
    EPS surprise
    +8,2 %
    reported vs consensus · beat
    Revenue surprise
    +0,6 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$2,25
    MeanA$2,57
    MedianA$2,40
    HighA$3,85
    SpotA$2,21
    +16.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,9 %Above median
    Net Margin4,4 %Below median
    ROE18,9 %Above P75
    Capex / Rev-1,1 %Above P75
    D/E1,69Bottom quartile
    Cash Conv5,64Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ACL.AX Market data — financials · 2026-05-27
    • Australian Clinical Labs Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Melinda McgrathChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ACL.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage